What Is Orexin, and Why Is It Showing Up in Post-Viral Fatigue Research?
A 2026 review proposes orexin, a signaling molecule made in the brain, as a link between post-viral fatigue, sleep, and blood sugar.
Photo: Sarah Shull / Unsplash
Orexin is a small signaling molecule made in the hypothalamus. It regulates arousal and neuroendocrine function, and plays a part in how the body handles glucose. A review published in Endocrine Reviews in September 2026 proposes it as a central link between the stress response, immune activation, and the metabolic changes that follow some viral infections. The authors also point to GLP-1 drugs as one direction for future treatment research.
The rest of the post-viral writing is gathered in the chronic fatigue hub.
What orexin does when it is working
Orexin, also called hypocretin, is made by a small population of neurons in the lateral hypothalamus. The clearest picture of its job comes from what happens when those cells are lost.
Bassetti and colleagues published a 2019 review in Nature Reviews Neurology. They describe narcolepsy type 1 as a disorder reflecting a selective loss or dysfunction of exactly those neurons. The result isn't only sleepiness. They present it as a hypothalamic disorder affecting sleep and wakefulness along with motor, psychiatric, emotional, cognitive, metabolic, and autonomic function.
That list is why the orexin idea is being taken seriously. It is one signal whose failure produces a scattered, multisystem picture. Which is roughly what post-viral illness looks like from the outside.
What the review proposes
Ruhrländer and colleagues work at a post-COVID coordination center in Marburg, Germany, and their review focuses on two conditions. One is long COVID, which researchers call post-acute sequelae of COVID-19, or PASC. The other is ME/CFS, short for myalgic encephalomyelitis/chronic fatigue syndrome, which they describe as the most severe form of post-viral illness. Its features include severe fatigue, unrefreshing sleep, neurocognitive impairment, autonomic and immune dysregulation, and post-exertional malaise (a crash after activity that can arrive a day or two later). The authors note that many long COVID cases also meet the criteria for ME/CFS.
Their argument starts from a resemblance. When the orexin system stops working properly, the result looks a lot like these conditions: fatigue, sleep problems, impaired glucose metabolism, and neuropsychiatric symptoms. From that overlap, they build a model in which weakened orexin signaling contributes to the hormonal and metabolic problems that follow a viral infection. The review then works through how orexin affects glucose metabolism and the body's stress-hormone system, and how those effects differ between men and women.
Why fatigue and blood sugar keep turning up together
Fatigue and blood sugar changes after a viral illness often show up together, and researchers have documented the pairing.
Scherer, Kirwan, and Rosen wrote in eLife in 2022 that metabolic dysfunction is a predisposing risk factor for severe acute COVID-19. They added that emerging evidence suggests this factor, combined with a chronic inflammatory state, may predispose to PASC. They were direct about the limits. At that point the syndrome lacked a clear definition, prevalence, or cause.
Newer work puts a number on the forward direction. Sanhueza and colleagues followed 60 people after COVID-19. Among the 36 who had no glucose metabolism disorder beforehand, 24 had developed insulin resistance four months later, so two in three of them. Their study is about neutrophil behavior rather than fatigue, so it says nothing about symptoms. What it does establish is that metabolic change after a virus is measurable and common. That is the observation an orexin model would have to account for.
Where GLP-1 comes in
GLP-1 is a hormone the gut releases after you eat. It helps the pancreas release insulin and signals fullness, and drugs like semaglutide are built to mimic it. The review pairs GLP-1 with orexin as a second key regulator of metabolism. The authors also point to its effects beyond blood sugar, describing it as neuroprotective, anti-inflammatory, protective of blood vessels, and able to modulate the immune system. Those effects are what make it interesting for post-viral illness. So the authors name GLP-1 receptor agonists, along with drugs that act on the orexin system, as emerging treatment strategies worth exploring.
That puts GLP-1 drugs on the research agenda for long COVID and ME/CFS. No published randomized trial has tested them in either condition yet, so whether they help is still an open question. If you see this paper summarized as proof that GLP-1 drugs treat long COVID, check whether the summary cites a trial in these patients.
What's been measured so far
Orexin has been measured before in a fatiguing neuroinflammatory illness. Constantinescu and colleagues sampled cerebrospinal fluid from 34 people with multiple sclerosis, 24 with other inflammatory neurological disease, and 42 with non-inflammatory disease. Orexin A was slightly decreased in the inflammatory group. In MS itself there was no evidence of orexin A deficiency, only a slight drop that could have been chance. The authors reported no significant link between orexin A levels and either fatigue or sleepiness.
Different disease, small sample. It settles nothing about post-viral illness, but it shows the measurement is possible and that a link with fatigue can't be assumed. The closest direct evidence so far is in mice. A 2026 study found that COVID infection lowered orexin in the hypothalamus and kept it low, while flu didn't. Nobody has yet run the same check in people with long COVID or ME/CFS, so for now the model is a hypothesis with decent circumstantial support.
What this changes for a fatigue workup
What changes today is the question you can bring to your clinician. Fatigue, unrefreshing sleep, and unpredictable blood sugar are often handled as three separate problems in a chart. There is now a published argument in a major endocrinology journal that they may share a regulator. That is a reason to ask whoever manages your care whether your glucose handling has been looked at properly, instead of assumed to be fine.
If blood sugar is the piece you want to understand, what a normal A1c alongside a high fasting insulin means covers how those two numbers separate. For the wider argument about what ties these symptoms together, the unified model of ME/CFS approached it from a different direction. And if you are wondering whether any of this is specific to COVID, what happens after RSV and flu suggests it isn't.
If chronic fatigue is part of your picture, ME/CFS, Reconsidered is an upcoming course on ME/CFS, post-viral fatigue, and pacing. You can join The Weekly Well, our free newsletter, to hear when the course opens.
FAQ
What is orexin, in plain terms?
Orexin, also called hypocretin, is a signaling peptide. It is made by a small group of neurons in the lateral hypothalamus. It regulates arousal, metabolism, and neuroendocrine function, and it has a hand in how the body handles glucose. Its role is clearest in narcolepsy type 1, which a 2019 review describes as reflecting a selective loss or dysfunction of those same neurons.
Does this review mean GLP-1 drugs treat long COVID?
Not yet. The review names GLP-1 receptor agonists as an emerging treatment strategy worth studying. No published randomized trial has tested this drug class in long COVID or ME/CFS, so there isn't evidence yet on whether it helps. Any decision about a prescription medication belongs with the clinician who prescribes it.
Has anyone measured orexin in people with ME/CFS or long COVID?
Not in people yet. The 2026 paper is a review that builds its case on the resemblance between orexin dysfunction and post-viral symptoms. A 2026 mouse study found that COVID infection lowered orexin in the brain, while flu didn't. In people, orexin has been measured in spinal fluid in multiple sclerosis, where a 2011 study found no significant link with fatigue or sleepiness, so the connection can't be assumed.
Why would a virus change my blood sugar?
Several lines of work point that way, though the mechanism is unsettled. A 2022 eLife article argued that metabolic dysfunction and chronic inflammation may together predispose to post-acute COVID-19. A 2026 study of 60 people found that 24 of the 36 with no prior glucose problem, so two in three of them, had developed insulin resistance four months after infection. The orexin model is one proposed explanation for why these travel together.
Is a review the same as a study?
No. A review gathers existing work and proposes a way to read it, so its value is in the synthesis rather than in new measurements. This one is published in a well-regarded endocrinology journal, and its mechanistic argument is serious. It still contains no new patient data, no control group, and no tested treatment.
References
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
